Prior view was $11.88-$12.08. FY25 consensus $11.97.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie sees $1.50 per share unfavorable impact in Q3 from milestones expense
- AbbVie sees Q3 adjusted EPS $1.74-$1.78 with IPR&D, milestones expense
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- AbbVie price target raised to $251 from $220 at BofA
- AbbVie’s Phase 2 HIV Study Completion: Potential Market Impact